RxDoctor Payments Data

Candice Blackwood

Family · Decatur, ALNPI 1306516893

Payments from drug & device makers

$1,215in general payments, 2019–2025

Across 67 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$318
  • Novo Nordisk$313
  • Lilly USA, LLC$133
  • Exact Sciences$118
  • AstraZeneca$104
  • Pfizer$62
  • plus $168 from 5 others

What the payments were for

  • Food & beverage$1,215100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,215 in reported general payments places this provider in the 65th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$17,468
Medicare patients
127
Services billed
391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide72$97,381
OzempicSemaglutide81$94,217
EliquisApixaban58$46,890
FarxigaDapagliflozin Propanediol29$30,938
JardianceEmpagliflozin23$28,782
TrulicityDulaglutide14$20,920
EntrestoSacubitril/Valsartan21$19,621
Repatha SureclickEvolocumab24$18,831
LinzessLinaclotide20$18,773
XareltoRivaroxaban21$18,610
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$18,308
MyrbetriqMirabegron14$9,420
Rosuvastatin Calcium276$4,774
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$3,248
Levothyroxine Sodium207$2,986

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$133$118,30186 claims
Novo NordiskOzempic$313$94,21781 claims
PfizerEliquis$62$46,89058 claims
AstraZenecaFarxiga$104$30,93829 claims
NovartisEntresto$29$19,62121 claims
AbbVieLinzess$49$18,77320 claims
GSKTrelegy Ellipta$58$18,30819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,415 family providers in Alabama.

Other family in Decatur

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →